Huynh Hoang-Long, Fan Lena, Germosen Carmen, Bucovsky Mariana, Colon Ivelisse, Kil Nayoung, Agarwal Sanchita, Walker Marcella
Division of Endocrinology, Columbia University Irving Medical Center, New York, NY 10032, United States of America.
Bone Rep. 2022 May 10;16:101589. doi: 10.1016/j.bonr.2022.101589. eCollection 2022 Jun.
Thiazide diuretics, a commonly used class of anti-hypertensives, have been associated with increased areal bone mineral density (aBMD). Data regarding effects on fracture are conflicting and no information is available regarding effects on skeletal microstructure and mechanical competence.
We compared skeletal microstructure, volumetric BMD (vBMD), stiffness and prevalent fractures in current thiazide diuretic users and non-users from a population-based multiethnic cohort of elderly adults age ≥ 65 years ( = 599) with high resolution peripheral quantitative computed tomography (HR-pQCT) and micro-finite element analysis.
Female current thiazide diuretic users had higher weight and BMI and were more likely to be non-Caucasian compared to non-users. There were no differences in age, historical fractures or falls between female users and non-users. Female thiazide users tended to have lower calcium and vitamin d intake compared to non-users. After adjusting for age, weight, race and other covariates, 1/3-radius mean aBMD by dual energy x-ray absorptiometry (DXA) was 3.2% ( = 0.03) higher in female users vs. non-users. By HRpQCT, adjusted mean cortical vBMD was 2.4% ( = 0.03) higher at the radius in female users vs. non-users, but there was no difference in stiffness. DXA results were similar in the subset of Black females. There was no difference in any adjusted aBMD or cortical skeletal parameters by DXA or HRpQCT respectively in males.
Thiazide use was associated with a modestly higher aBMD at the predominantly cortical 1/3-radius site and radial cortical vBMD by HRpQCT in females. The effect on cortical bone may offer skeletal benefits in women taking thiazides for other indications such as hypertension, hypercalciuria or recurrent nephrolithiasis.
噻嗪类利尿剂是一类常用的抗高血压药物,与骨面积骨密度(aBMD)增加有关。关于其对骨折影响的数据存在冲突,且尚无关于其对骨骼微观结构和力学性能影响的信息。
我们使用高分辨率外周定量计算机断层扫描(HR-pQCT)和微有限元分析,比较了年龄≥65岁的基于人群的多民族老年队列(n = 599)中当前使用噻嗪类利尿剂的人群和未使用人群的骨骼微观结构、体积骨密度(vBMD)、骨硬度和既往骨折情况。
与未使用者相比,当前使用噻嗪类利尿剂的女性体重和体重指数更高,且更有可能是非白种人。女性使用者和未使用者在年龄、既往骨折或跌倒情况方面没有差异。与未使用者相比,噻嗪类利尿剂使用者的钙和维生素D摄入量往往较低。在调整年龄、体重、种族和其他协变量后,通过双能X线吸收法(DXA)测量的1/3半径处平均aBMD,女性使用者比未使用者高3.2%(P = 0.03)。通过HRpQCT测量,调整后的平均皮质vBMD在女性使用者的桡骨处比未使用者高2.4%(P = 0.03),但骨硬度没有差异。在黑人女性亚组中,DXA结果相似。男性在DXA或HRpQCT测量的任何调整后aBMD或皮质骨骼参数方面均无差异。
在女性中,使用噻嗪类利尿剂与主要为皮质骨的1/3半径部位aBMD适度升高以及通过HRpQCT测量的桡骨皮质vBMD升高有关。对皮质骨的这种影响可能会为因高血压、高钙尿症或复发性肾结石等其他适应症而服用噻嗪类药物的女性带来骨骼益处。